180 related articles for article (PubMed ID: 17260141)
1. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
van Essen M; Krenning EP; Bakker WH; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1219-27. PubMed ID: 17260141
[TBL] [Abstract][Full Text] [Related]
2. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
van Essen M; Krenning EP; Kam BL; de Herder WW; Feelders RA; Kwekkeboom DJ
J Nucl Med; 2010 Mar; 51(3):383-90. PubMed ID: 20150247
[TBL] [Abstract][Full Text] [Related]
5. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
[TBL] [Abstract][Full Text] [Related]
6. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.
van Vliet EI; Hermans JJ; de Ridder MA; Teunissen JJ; Kam BL; de Krijger RR; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2012 Sep; 53(9):1359-66. PubMed ID: 22782312
[TBL] [Abstract][Full Text] [Related]
7. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
[TBL] [Abstract][Full Text] [Related]
8. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ
J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
Kwekkeboom DJ; Teunissen JJ; Bakker WH; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; Esser JP; Kam BL; Krenning EP
J Clin Oncol; 2005 Apr; 23(12):2754-62. PubMed ID: 15837990
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids.
He J; Zhou J; Lu Z
Chin Med J (Engl); 1995 May; 108(5):338-41. PubMed ID: 7555233
[TBL] [Abstract][Full Text] [Related]
11. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571
[TBL] [Abstract][Full Text] [Related]
14. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
de Keizer B; van Aken MO; Feelders RA; de Herder WW; Kam BL; van Essen M; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):749-55. PubMed ID: 18210106
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
[TBL] [Abstract][Full Text] [Related]
16. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
[TBL] [Abstract][Full Text] [Related]
17. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
18. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW; Hofman MS; Thomson BN; Hicks RJ
Eur J Surg Oncol; 2012 Jan; 38(1):64-71. PubMed ID: 21906907
[TBL] [Abstract][Full Text] [Related]
19. Bronchial and Thymic Carcinoid Tumors.
Litvak A; Pietanza MC
Hematol Oncol Clin North Am; 2016 Feb; 30(1):83-102. PubMed ID: 26614370
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]